BX enters this week as one of the more constructive setups in alternative asset management: short sellers have cut their positions sharply, the stock is close to flat on the week despite broader market chop, and a burst of high-profile deal activity is putting Blackstone's deployment firepower front and centre.
The most striking positioning move this week is the dramatic unwind in short interest. At 2.2% of the free float, short interest has fallen roughly 25% over the past five trading sessions — one of the sharpest weekly reductions in the stock's recent history. That follows a period in mid-to-late April when shorts briefly built to around 3.1% of float before pulling back rapidly post-earnings. Borrow availability remains very wide, consistent with a stock where the lending pool is far from stressed. Cost to borrow ticked up 10% on the week to 0.53% — a modest absolute level that reflects easy supply rather than any squeeze dynamic. The ORTEX short score has drifted lower to 32.4, down from a local peak of 35.4 on May 4, reinforcing the picture of a short base that is retreating rather than building. Overall, positioning in the lending market looks relieved rather than re-energised.
Options traders are marginally more cautious. The put/call ratio has climbed to 1.59, nearly two standard deviations above its 20-day average of 1.52 — the most defensive tilt in roughly a month. That is still well below the 52-week high of 1.87, so this is a measured increase rather than a genuine options alarm. The gap between the options signal and the short-covering trend is the key tension in the setup this week: equity shorts are leaving, but derivatives hedgers are adding modest protection. The two don't contradict each other — they reflect different time horizons — but the divergence is worth noting.
The Street has been busy reacting to Q1 results reported on April 23, when the stock fell 6.2% on the day and shed another 3.2% over the following week. Analyst responses were mixed in direction but uniform in conviction — almost all kept existing ratings. Morgan Stanley trimmed its target from $215 to $184, a meaningful cut that still carries an Overweight. Goldman Sachs moved to $118, also a significant reduction from $158, while keeping Neutral. On the other side, Evercore raised its target from $135 to $150, and Oppenheimer upgraded to Outperform with a $154 target. The mean price target across the Street now sits at $143.90, implying roughly 17% upside to the current price of $122.76. Bulls point to Blackstone's leadership in alternatives and its structural access to institutional and high-net-worth capital; bears flag interest-rate sensitivity in its newer product verticals and recent redemption pressure in direct lending. The dividend score ranks in the 92nd percentile, a genuine differentiator in the asset manager peer group.
The deal news this week provides the most tangible fundamental colour. Blackstone launched a new long-hold fund expanding its $8 billion core private equity franchise. It struck a music catalogue deal with Sony Music Publishing. It is co-investing in a €600 million quantum computing funding round alongside Airbus. And it filed a Digital Infrastructure Trust IPO — BXDC — which would be another vehicle for retail capital access. These are exactly the deal-flow and product-launch signals that the bull case depends on: the argument that Blackstone can grow AUM even in a choppy deployment environment.
Among close peers, KKR fell 2.5% on the week and OWL dropped nearly 7%, while ARES was roughly flat and STEP added 2.1%. BX's near-zero weekly return looks like outperformance in context — particularly given how hard the stock was hit around the April earnings print. The next catalysts to watch are the pace of capital deployment from the new long-hold vehicle, any updates on BXDC pricing, and whether the options put/call ratio continues drifting higher or reverts as the post-earnings hedges roll off.
See the live data behind this article on ORTEX.
Open BX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
